why choose us

300×250 Ad Slot

Research Article: High dose IFN-?2b as post operative adjuvant therapy for acral melanoma: a multi-center real-world cohort study of 171 Chinese patients

Date Published: 2026-08-17

Abstract:
This study aimed to investigate recurrence patterns and survival outcomes in Chinese patients with AM who received postoperative adjuvant High-dose interferon (HD-IFN), and to assess how treatment duration and the interval between surgery and therapy initiation relate to recurrence and survival. A multi-center, retrospective cohort study involving 171 patients with AM who received postoperative adjuvant HD-IFN therapy between January 2012 and March 2025 was conducted at five melanoma diagnostic and treatment centers across China. The median follow-up duration was 75.7 months. Median recurrence-free survival (RFS) and overall survival (OS) were 37.5 and 93.7 months, respectively. Stratified by recurrence risk, patients in the low-risk, high-risk, and very high-risk groups had median RFS of 64.1, 31.6, and 13.8 months ( P = 0.035), and median OS of 131.9, 82.1, and 61.9 months, respectively ( P = 0.027). Results show that full-course HD-IFN treatment is statistically associated with improved survival in high-risk and very high-risk subgroups, whereas the timing of HD-IFN initiation within 3 months after surgery makes no significant difference to prognosis.

Introduction:
This study aimed to investigate recurrence patterns and survival outcomes in Chinese patients with AM who received postoperative adjuvant High-dose interferon (HD-IFN), and to assess how treatment duration and the interval between surgery and therapy initiation relate to recurrence and survival.

Read more

300×250 Ad Slot